BioSpace News Archive

Geron Corporation announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update on the Company’s business operations and clinical development programs on May 10, 2022, before the U.S. financial markets open.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the first presentation detailing the optimization and mechanism of action of its HMI-103 nuclease-free gene editing candidate for phenylketonuria (PKU) will take place during the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting May 16-19, 2022.

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

EdiGene, Inc., a global, clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, will present getools (gene editing data analysis toolkit) for advanced analytics of DNA and RNA editing efficiency and outcomes for therapeutic development at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

GC Biopharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 31 March 2022.

The global Single-cell Analysis market size is expected to hit around US$ 8.7 billion by 2030 and is anticipated to grow at a CAGR of 16.0% during forecast period 2021 to 2030.

The global transplantation market was estimated at USD 12.5 billion in 2021 and is expected to surpass around USD 31 billion by 2030 with a CAGR of 9.4% from 2022 to 2030.

The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to be worth around US$ 10.6 billion by 2030 from valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

Rising prevalence of chronic diseases, growing demand for telehealth and remote patient monitoring, and increasing need for automatic data entry systems to reduce manual errors are key factors expected to drive global market growth.